About Puma Biotechnology (NASDAQ:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:PBYI
- CUSIP: N/A
- Web: www.pumabiotechnology.com
- Current Ratio: 1.23%
- Quick Ratio: 1.23%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $2.11 per share
- Price / Book: 50.00
- Trailing EPS: ($8.19)
- Net Income: ($276,010,000.00)
- Return on Equity: -208.58%
- Return on Assets: -145.91%
- Employees: 160
- Outstanding Shares: 37,530,000
Frequently Asked Questions for Puma Biotechnology (NASDAQ:PBYI)
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) announced its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.50) by $0.43. The biopharmaceutical company had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company earned ($1.11) earnings per share. View Puma Biotechnology's Earnings History.
When will Puma Biotechnology make its next earnings announcement?
Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?
9 analysts have issued 1-year target prices for Puma Biotechnology's shares. Their predictions range from $92.00 to $164.00. On average, they anticipate Puma Biotechnology's stock price to reach $130.67 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Nektar Therapeutics (NKTR), Exact Sciences Corporation (EXAS), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Covance (CVD), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Anacor Pharmaceuticals (ANAC), INC Research Holdings (INCR), FibroGen (FGEN), Sage Therapeutics (SAGE), ACADIA Pharmaceuticals (ACAD) and Shire Viropharma (VPHM).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
- Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
- Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
- Steven Lo, Chief Commercial Officer (Age 50)
- Jay M. Moyes, Independent Director (Age 63)
- Adrian M Senderowicz, Independent Director (Age 53)
- Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
- Frank E. Zavrl, Independent Director (Age 51)
Who owns Puma Biotechnology stock?
Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
ADAGE CAPITAL PARTNERS GP, L.L.C.
(6.72%), Janus Henderson Group PLC (5.04%), Perceptive Advisors LLC (2.46%), Point72 Asset Management L.P. (1.28%), Emerald Advisers Inc. PA (0.99%) and Schroder Investment Management Group (0.93%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?
Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Canada Pension Plan Investment Board, C WorldWide Group Holding A S, Neuberger Berman Group LLC, California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC., Stifel Financial Corp and Principal Financial Group Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.
Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?
Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Nicholas Investment Partners LP, Emerald Advisers Inc. PA, Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Dimensional Fund Advisors LP and Sanctuary Wealth Advisors LLC. View Insider Buying and Selling for Puma Biotechnology.
How do I buy Puma Biotechnology stock?
Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of Puma Biotechnology stock can currently be purchased for approximately $105.50.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $3.96 billion. The biopharmaceutical company earns ($276,010,000.00) in net income (profit) each year or ($8.19) on an earnings per share basis. Puma Biotechnology employs 160 workers across the globe.
How can I contact Puma Biotechnology?
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Puma Biotechnology's mailing address is 10880 Wilshire Blvd Ste 2150, LOS ANGELES, CA 90024-4106, United States. The biopharmaceutical company can be reached via phone at +1-424-2486500 or via email at [email protected]
Analysts' Consensus Ratings for Puma Biotechnology (NASDAQ:PBYI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 8 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.89)|
|Consensus Price Target: ||$130.67 (23.85% upside)|Consensus Price Target History for Puma Biotechnology (NASDAQ:PBYI)
Analysts' Ratings History for Puma Biotechnology (NASDAQ:PBYI)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/10/2017||Credit Suisse Group||Boost Price Target||Outperform||$136.00 -> $142.00||N/A|
|11/10/2017||Barclays PLC||Reiterated Rating||Buy||$103.00 -> $122.00||N/A|
|11/10/2017||Citigroup Inc.||Boost Price Target||Buy -> Buy||$156.00 -> $164.00||N/A|
|11/10/2017||Royal Bank Of Canada||Lower Price Target||Sector Perform||$108.00 -> $92.00||N/A|
|10/27/2017||Leerink Swann||Boost Price Target||Positive -> Outperform||$140.00||N/A|
|10/9/2017||Bank of America Corporation||Reiterated Rating||Buy||$117.00 -> $135.00||N/A|
|10/4/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$131.00||High|
|10/2/2017||Stifel Nicolaus||Boost Price Target||Buy||$110.00 -> $130.00||Low|
|7/22/2017||Cowen and Company||Reiterated Rating||Outperform||$91.00 -> $120.00||Medium|
|1/5/2016||Berenberg Bank||Upgrade||Hold -> Buy||N/A|
Earnings History for Puma Biotechnology (NASDAQ:PBYI)Earnings History by Quarter for Puma Biotechnology (NASDAQ PBYI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/7/2018|| || || || || || || || |
|11/9/2017||Q3 2017||($2.50)||($2.07)||$3.78 million||$6.10 million||View||N/A|
Earnings Estimates for Puma Biotechnology (NASDAQ:PBYI)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Puma Biotechnology (NASDAQ:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Puma Biotechnology (NASDAQ PBYI)
Insider Ownership Percentage: 21.10%Insider Trades by Quarter for Puma Biotechnology (NASDAQ PBYI)
Institutional Ownership Percentage: 95.41%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/29/2017||Richard Paul Bryce||SVP||Sell||15,000||$120.00||$1,800,000.00|| |
|9/7/2017||Richard Paul Bryce||SVP||Sell||15,000||$100.09||$1,501,350.00|| |
|7/20/2017||Alan H Auerbach||Insider||Sell||13,175||$94.73||$1,248,067.75|| |
|7/20/2017||Richard Paul Bryce||SVP||Sell||1,998||$94.48||$188,771.04|| |
|7/3/2017||Richard Paul Bryce||SVP||Sell||5,000||$87.10||$435,500.00|| |
|6/12/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||247,260||$80.32||$19,859,923.20|| |
|6/5/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||507,128||$87.84||$44,546,123.52|| |
|5/26/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||1,235,700||$75.38||$93,147,066.00|| |
|2/1/2017||Robert Charnas||Insider||Sell||3,008||$31.83||$95,744.64|| |
|1/20/2017||Alan H Auerbach||Insider||Sell||10,202||$33.24||$339,114.48|| |
|1/20/2017||Richard Paul Bryce||SVP||Sell||2,293||$33.24||$76,219.32|| |
|7/6/2015||Richard Paul Bryce||SVP||Sell||3,000||$110.03||$330,090.00|| |
|11/8/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||22,549||$38.92||$877,607.08|| |
|11/5/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||280,700||$39.60||$11,115,720.00|| |
|10/9/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||140,900||$40.44||$5,697,996.00|| |
|12/18/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||29,560||$19.00||$561,640.00|| |
|12/12/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||30,400||$19.00||$577,600.00|| |
|12/11/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||140,040||$18.98||$2,657,959.20|| |
|10/24/2012||Thomas Malley||Director||Buy||10,000||$16.00||$160,000.00|| |
|10/18/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||610,000||$16.00||$9,760,000.00|| |
Headline Trends for Puma Biotechnology (NASDAQ:PBYI)
Latest Headlines for Puma Biotechnology (NASDAQ PBYI)
Puma Biotechnology (NASDAQ PBYI) Chart for Friday, November, 17, 2017